Cullinan Therapeutics (CGEM) Change in Accured Expenses (2020 - 2026)

Cullinan Therapeutics' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$4.3 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 18.04% year-over-year to -$4.3 million; the TTM figure through Mar 2026 stood at $9.0 million (up 73.61% YoY), while the FY2025 annual figure was $8.0 million, up 177.24% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$4.3 million, down from $6.2 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $6.9 million in Q4 2024, with the low at -$7.5 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is $1.6 million (2025), against an average of $1.5 million.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses sank 385.19% in 2024, then surged 8948.39% in 2025.
• Cullinan Therapeutics' Change in Accured Expenses stood at $1.6 million in 2022, then soared by 219.77% to $5.1 million in 2023, then soared by 36.11% to $6.9 million in 2024, then dropped by 10.26% to $6.2 million in 2025, then sank by 169.66% to -$4.3 million in 2026.
• Business Quant data shows CGEM's Change in Accured Expenses at -$4.3 million in Q1 2026, $6.2 million in Q4 2025, and $5.5 million in Q3 2025.